Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.
You may also be interested in...
British Medical Journal Apologizes To Lilly For Prozac Article
In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”
British Medical Journal Apologizes To Lilly For Prozac Article
In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”
Prozac Documents Deemed "Missing" Were Already Available, Lilly Says
The documents which appeared in the British Medical Journal were shared with FDA, published in medical journals or produced through legal discovery over 10 years ago, Lilly says. The company maintains the medical journal "published data without validating the information."